...
首页> 外文期刊>MBio >Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target
【24h】

Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target

机译:2型NADH脱氢酶是电子进入无名链球菌呼吸链的唯一入口,并且是潜在的药物靶标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

ABSTRACT The opportunistic pathogen Streptococcus agalactiae is the major cause of meningitis and sepsis in a newborn’s first week, as well as a considerable cause of pneumonia, urinary tract infections, and sepsis in immunocompromised adults. This pathogen respires aerobically if heme and quinone are available in the environment, and a functional respiratory chain is required for full virulence. Remarkably, it is shown here that the entire respiratory chain of S.?agalactiae consists of only two enzymes, a type 2 NADH dehydrogenase (NDH-2) and a cytochrome bd oxygen reductase. There are no respiratory dehydrogenases other than NDH-2 to feed electrons into the respiratory chain, and there is only one respiratory oxygen reductase to reduce oxygen to water. Although S.?agalactiae grows well in vitro by fermentative metabolism, it is shown here that the absence of NDH-2 results in attenuated virulence, as observed by reduced colonization in heart and kidney in a mouse model of systemic infection. The lack of NDH-2 in mammalian mitochondria and its important role for virulence suggest this enzyme may be a potential drug target. For this reason, in this study, S.?agalactiae NDH-2 was purified and biochemically characterized, and the isolated enzyme was used to screen for inhibitors from libraries of FDA-approved drugs. Zafirlukast was identified to successfully inhibit both NDH-2 activity and aerobic respiration in intact cells. This compound may be useful as a laboratory tool to inhibit respiration in S.?agalactiae and, since it has few side effects, it might be considered a lead compound for therapeutics development. IMPORTANCE S.?agalactiae is part of the human intestinal microbiota and is present in the vagina of ~30% of healthy women. Although a commensal, it is also the leading cause of septicemia and meningitis in neonates and immunocompromised adults. This organism can aerobically respire, but only using external sources of heme and quinone, required to have a functional electron transport chain. Although bacteria usually have a branched respiratory chain with multiple dehydrogenases and terminal oxygen reductases, here we establish that S.?agalactiae utilizes only one type 2 NADH dehydrogenase (NDH-2) and one cytochrome bd oxygen reductase to perform respiration. NADH-dependent respiration plays a critical role in the pathogen in maintaining NADH/NAD~(+)redox balance in the cell, optimizing ATP production, and tolerating oxygen. In summary, we demonstrate the essential role of NDH-2 in respiration and its contribution to S.?agalactiae virulence and propose it as a potential drug target.
机译:摘要机会性病原体无乳链球菌是新生儿头一周的脑膜炎和败血症的主要原因,也是免疫力低下的成年人的肺炎,尿路感染和败血症的重要原因。如果环境中有血红素和醌,则该病原菌可有氧呼吸,并且要获得充分的毒力,需要功能性呼吸链。值得注意的是,这里显示了加拉加特酵母的整个呼吸链仅由两种酶组成,即2型NADH脱氢酶(NDH-2)和细胞色素bd氧还原酶。除NDH-2外,没有其他呼吸脱氢酶可以将电子馈入呼吸链,并且只有一种呼吸氧还原酶可以将氧气还原为水。尽管agalactiae通过发酵代谢在体外生长良好,但此处显示,如在全身性感染小鼠模型中心脏和肾脏中的定植减少所观察到的,缺乏NDH-2会导致毒力减弱。哺乳动物线粒体中NDH-2的缺乏及其对毒力的重要作用表明该酶可能是潜在的药物靶标。由于这个原因,在这项研究中,纯化了agalactiae NDH-2并对其进行了生化表征,然后使用分离出的酶从FDA批准的药物库中筛选抑制剂。扎鲁司特被确定可成功抑制完整细胞中的NDH-2活性和有氧呼吸。该化合物可作为实验室工具来抑制河豚链球菌的呼吸作用,并且由于它几乎没有副作用,因此可能被认为是治疗药物开发的先导化合物。重要信息agalactiae是人类肠道菌群的一部分,约30%的健康女性的阴道中存在。尽管这是一种表彰,但它也是新生儿和免疫功能低下的成年人败血症和脑膜炎的主要原因。这种有机体可以有氧呼吸,但只能使用具有功能性电子传输链所需的外部血红素和醌源。尽管细菌通常具有带有多个脱氢酶和末端氧还原酶的分支呼吸链,但在此我们确定agalactiae仅利用一种2型NADH脱氢酶(NDH-2)和一种细胞色素bd氧还原酶来进行呼吸。依赖NADH的呼吸在病原体中在维持细胞中NADH / NAD〜(+)氧化还原平衡,优化ATP产生和耐受氧气方面起着至关重要的作用。总之,我们证明了NDH-2在呼吸作用中的重要作用及其对agalactiae毒力的贡献,并将其作为潜在的药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号